Afuco™ Anti-CD4 ADCC Therapeutic Antibody (Ibalizumab), ADCC Enhanced
This product is an ADCC enhanced antibody produced by our Afuco™ platform. Recombinant monoclonal antibody to CD4. Ibalizumab (TMB-355 previously known as TNX-355) is a non-immunosuppressive monoclonal antibody that binds CD4, the primary receptor for HIV, and inhibits the viral entry process. It is being investigated as an HIV entry inhibitor with the ability to block both CCR5- and CXCR4-tropic viruses.
| Supplier | Creative Biolabs |
|---|---|
| Product # | AFC-TAB-146 |
| Pricing | Inquiry |
| Host | Human |
| Target | CD4 |
| Species Reactivity | Human |
| Type | ADCC enhanced antibody |
| Applications | FuncS, IF, Neut, ELISA, FC, IP |
| Storage | Store at +4°C short term (1-2 weeks). Aliquot and store at -20°C long term. Avoid repeated freeze/thaw cycles. |